by Portfolio Grader | October 24, 2012 10:06 am
The grades of eight Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Dyax (NASDAQ:DYAX) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Dyax is engaged in the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The stock price has risen 19% over the past month, better than the 6% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of DYAX stock.
Aegerion Pharmaceuticals (NASDAQ:AEGR) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 37.2% over the past month. For more information, get Portfolio Grader’s complete analysis of AEGR stock.
The rating of Sinovac Biotech (NASDAQ:SVA) moves up this week, rising from a C to a B. Sinovac Biotech researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. Wall Street has pushed the stock higher by 25.9% over the past month. For more information, get Portfolio Grader’s complete analysis of SVA stock.
3SBio (NASDAQ:SSRX) boosts its rating from a C to a B this week. 3SBio is a biotechnology company that engages in the research and development, manufacture, and distribution of pharmaceutical products in the Peoples Republic of China. For more information, get Portfolio Grader’s complete analysis of SSRX stock.
Neurocrine Biosciences (NASDAQ:NBIX) shows solid improvement this week. The company’s rating rises from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
This week, Maxygen‘s (NASDAQ:MAXY) ratings are up from a C last week to a B. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock currently has a trailing PE Ratio of 3.30. For more information, get Portfolio Grader’s complete analysis of MAXY stock.
This is a strong week for Novavax (NASDAQ:NVAX). The company’s rating climbs to B from the previous week’s C. Novavax creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. Wall Street seems to agree with the upgrade and has propelled the stock up 7.9% over the past month. For more information, get Portfolio Grader’s complete analysis of NVAX stock.
This week, Allos Therapeutics (NASDAQ:ALTH) pushes up from a C to a B rating. Allos is a biopharmaceutical company focused on developing and commercializing small-molecule drugs that treat cancer. For more information, get Portfolio Grader’s complete analysis of ALTH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/10/8-biotechnology-stocks-to-buy-now-dyax-aegr-sva/
Short URL: http://invstplc.com/1fqG3cW
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.